NCT00313950View on ClinicalTrials.gov

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

470

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

April 30, 2010

Conditions
MeaslesMumpsRubellaHepatitis A
Interventions
BIOLOGICAL

Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella

0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)

BIOLOGICAL

Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine

0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)

BIOLOGICAL

Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella

0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)

Trial Locations (1)

Unknown

Izmir

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine | Biotech Hunter | Biotech Hunter